New Healthcare market report from Business Monitor International: "Netherlands Pharmaceuticals & Healthcare Report Q4 2013"

Boston, MA -- (SBWire) -- 09/12/2013 --We maintain our subdued outlook on the Dutch pharmaceutical and healthcare sector for the remainder of 2013 and looking forward into 2014. With further essential structural reform to the public sector on the horizon, leading to excessive budget deficits, we see economic recovery being put on hold. We therefore do not expect the pharmaceutical industry to return to positive growth until 2016 at the earliest. The Dutch on average spend 14% less on medicines than the rest of Western Europe, and uptake of generic medicines, encouraged by patent expiries and insurers' preference policies, will result in continuing negative pressures on volume consumption and prices of medicines.

Headline Expenditure Projections

- Pharmaceuticals: EUR6.88bn (US$8.74bn) in 2012 to EUR6.81bn (US$9.06bn) in 2013; -1.0% in local currency terms and 3.7% in US dollar terms. Forecast revised upwards due to incorporation of hospitals sales in historic data.
- Healthcare: EUR73.08bn (US$92.81bn) in 2012 to EUR74.15bn (US$98.62bn) in 2013; 1.5% in local currency terms and +6.3% in US dollar terms. Local currency forecast revised upwards from previous quarter.

View Full Report Details and Table of Contents

Risk/Reward Ratings: The Netherlands has been shifted downwards in BMI's Q413 RRRs for the 13 key Western European markets. The Netherlands weighs in at eighth in our ratings, having fallen from seventh in Q313. While at 66 its overall RRR score (slightly below the regional average of 67) has not changed from the previous quarter, the inclusion of Austria in our ratings this quarter means that the Netherlands has been pushed down. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.

Key Trends And Developments

- Data published by the Central Bureau for Statistics (CBS) in July stated that in 2012, healthcare spending in the Netherlands amounted to EUR92.7bn (US$120.56bn), a 3.7% increase from EUR87.28bn (US $113.51bn) in 2011. This highlights the problem of rising healthcare costs for the government, which currently accounts for around 86% of healthcare expenditure. The government-funded Exceptional Medical Expenses Act (AWBZ) budget can no longer cover the costs of medical care, and its deficit since 2009 has increased annually by more than EUR3bn (US$4bn). As a result, the government is now considering restricting some of the conditions of the AWBZ.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends for January 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2013
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
- Partnerships, Licensing, Investments and M&A Deals and Trends for February 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends for April 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals
- Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012
- Bayer Healthcare Pharmaceuticals - SWOT, Strategy and Corporate Finance Report
- Fortis Healthcare Limited (FORTIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile